RPE65 and inherited retinal dystrophy: Voretigene Neparvovec (VN; brand name Luxturna®, Spark Therapeutics Inc., Philadelphia, PA, USA) is the first in vivo gene therapy for the eye approved for the treatment of retinal degeneration in patients affected by inherited retinal dystrophy caused by biallelic mutations in the RPE65 gene.